The Association of Fibrate Use with Kidney Outcomes and Mortality
- 7 April 2025
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (6) , 779-787
Abstract
Key Points: In this large national cohort of United States veterans followed over 14 years, fibrate was associated with a higher risk of incident CKD. Fibrate use was also associated with a lower risk of ESKD and all-cause mortality. Considering the potential long-term benefits, clinicians should not necessarily avoid fibrate use, with careful monitoring of kidney function. Background: Fibrate use can result in an acute increase in serum creatinine, making assessing kidney outcomes associated with fibrates difficult in studies with short follow-up times. In addition, there is limited research on certain kidney outcomes and mixed results of past studies. The aim of this study was to examine the association of fibrate use with incident CKD, ESKD, and mortality in a large national cohort of United States (US) Veterans. Methods: A retrospective cohort study was conducted to examine the association of de novo prescription of fibrate medications with incident CKD, ESKD, and mortality over up to 14 years of follow-up. Patients (N=688,382) were selected from the national Department of Veterans Affairs (VA) research database. Associations were examined in Cox proportional hazards model and Fine-Gray model adjusted for demographics, major comorbidities, laboratory measurements including baseline eGFR, albuminuria, and medications. Results: We identified 58,773 incident new fibrate users. The overall mean (SD) age was 59 (13) years, with 7% female, 18% Black, and 7% Hispanic. Fibrate users were more likely to be male, White, current smokers, and had higher frequencies of comorbidities. In the fully adjusted model, fibrate use (versus nonuse) was associated with a lower risk of death (hazard ratio, 0.91; 95% confidential interval, 0.89 to 0.93) and ESKD (0.80, 0.71 to 0.92) but with a higher risk of incident CKD (1.21, 1.19 to 1.24). Conclusions: In this large national cohort of US Veterans with long follow-up time, fibrate use was associated with a higher risk of incident CKD but a lower risk of ESKD and mortality. Further studies are needed to corroborate the potential benefits of fibrate on kidney function and survival.Keywords
Funding Information
- U.S. Department of Veterans Affairs (I01HX002680)
- Long Beach VA Medical Center
- U.S. Department of Veterans Affairs
- Veterans Health Administration Office of Research and Development
- VA Information and Resource Center (project No. SDR 02-237 and 98-004)
This publication has 26 references indexed in Scilit:
- Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney diseaseLife Sciences, 2023
- Association of Uric Acid–Lowering Therapy With Incident Chronic Kidney DiseaseJAMA Network Open, 2022
- Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 DiabetesKidney International Reports, 2019
- Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis developmentNature Medicine, 2014
- Effects of Fibrates in Kidney DiseaseJACC, 2012
- The incident user design in comparative effectiveness researchPharmacoepidemiology and Drug Safety, 2012
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyDiabetologia, 2010
- Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy PeopleAmerican Journal of Kidney Diseases, 2008
- PPARα agonist fenofibrate improves diabetic nephropathy in db/db miceKidney International, 2006
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005